Johnson & Johnson reported a strong finish to the year, overcoming the disruption of the global pandemic on some parts of its business like medical devices.
Meanwhile, Johnson & Johnson also is testing a two-dose vaccine as a backup and should have results on that in 2021's second half.
The pandemic, and the associated deferral of many medical procedures, reduced sales of surgery, vision care and orthopedics products.
Prescription drug sales jumped 16.3%, to $12.27 billion, led by immune disorder drug Stelara and cancer drugs Darzelex, Imbruvica and Erleada.
For all of 2020, Johnson & Johnson reported revenue of $82.58 billion, up just 0.6% from 2019, and net income of $14.71 billion, which was 2.7% below 2019's net income.